Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12687213 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL6112147 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL4771419 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL2040956 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL2040833 | 0.75 | DYRK1A (0.43) | DYRK1AALDH1A1 | |
| SCHEMBL9928532 | 0.71 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL11306761 | 0.71 | DYRK1A (0.37) | DYRK1AKDM4EALDH1A1 | |
| SCHEMBL5356031 | 0.71 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL22430373 | 0.71 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL5308681 | 0.70 | DYRK1A (0.46) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | claimed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2008152394-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-4639265-A | PRE- AND POSTEMERGENCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0064804-B1 | THIOPHENE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
| US-4547217-A | ESPECIALLY FOR CORN | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-10-15 | — | — | US | disclosed |
| US-4441910-A | PRE- AND POST-EMERGENCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-04-10 | — | — | US | disclosed |
| EP-0064804-A2 | Thiophene herbicides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | DYRK1A 1245/4885KDM4E 2045/4885ALDH1A1 1403/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | DYRK1A 1245/4885KDM4E 2045/4885ALDH1A1 1403/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | DYRK1A 1826/4885KDM4E 3284/4885ALDH1A1 159/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | DYRK1A 1586/4885KDM4E 1307/4885ALDH1A1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.